0001077183-22-000083.txt : 20220511 0001077183-22-000083.hdr.sgml : 20220511 20220511170209 ACCESSION NUMBER: 0001077183-22-000083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220505 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220511 DATE AS OF CHANGE: 20220511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35756 FILM NUMBER: 22914594 BUSINESS ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 BUSINESS PHONE: 2397680600 MAIL ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 8-K 1 neo-20220505.htm 8-K neo-20220505
0001077183FALSE00010771832022-05-052022-05-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 5, 2022
 
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
001-35756
74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 
9490 NeoGenomics Way,Fort Myers,Florida33912
(Address of principal executive offices)(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Recommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Common stock ($0.001 par value)NEOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Dr. Clive Morris Retirement
On May 5, 2022, Dr. Clive D. Morris, NeoGenomics, Inc.’s (the “Company”) current President of Inivata, informed the Company of his intention to retire from his role effective June 30, 2022. At this time, the terms of Mr. Morris’s settlement agreement with the Company have not been determined. The Company will file an amendment to this Current Report on Form 8-K disclosing any such additional information if and when it has been determined.
Vishal Sikri Appointment
On May 9, 2022, the Company announced that Vishal Sikri, age 46, was appointed President and Chief Commercial Officer, Inivata Division, of the Company, effective May 23, 2022 (the “Effective Date”). Prior to joining the Company, from July 2021 to May 2022, Mr. Sikri served as President of Oncology for Invitae Corp., a biotechnology company specializing in genetic diagnostics testing, and from February 2021 to May 2022, he served as Senior Vice President of Oncology Product Strategy and Management. Prior to Invitae, Mr. Sikri spent four years with Biocartis, a commercial stage molecular diagnostics company, serving as U.S. General Manager from April 2017 to February 2021. Mr. Sikri also served as Vice President of Commercial Operations for Sysmex Inostics, a biotechnology company specializing in blood-based cell-free tumor DNA oncology testing services, from January 2007 to May 2010. Prior to Sysmex Inostics, Mr. Sikri served as Senior Product Specialist for Abbott Laboratories, an American multinational medical devices and health care company, from December 1999 to October 2005, and as Product Manager for Abbott Laboratories from October 2005 to January 2007. Mr. Sikri received a B.S. from Beloit College, an M.S. from the University of Wisconsin-Madison, and an M.B.A. from Loyola University of Chicago – Graduate School of Business.
In connection with this new role, the Company and Mr. Sikri entered into a standard executive officer Employment Agreement (the “Employment Agreement”) which provides that Mr. Sikri’s base salary will be $510,000 per year, with annual review and adjustment at the discretion of the Board of Directors of the Company (the “Board”) or the Culture and Compensation Committee of the Board (the “Compensation Committee”), and an annual incentive bonus of 50% of annual salary based on the achievement of the Company’s corporate objectives and Mr. Sikri’s individual objectives, in each case, as established by the Board or the Compensation Committee; provided, however, that subject to the foregoing, Mr. Sikri’s annual bonus for the Company’s 2022 fiscal year will be $255,000. Mr. Sikri will also receive a $500,000 sign-on bonus within 30 days following the Effective Date. In addition, Mr. Sikri will be eligible for a new hire equity grant valued at $1,055,000.
Mr. Sikri is eligible to participate in the benefit plans and programs generally available to the Company’s employees, except to the extent such plans are duplicative of other benefits otherwise provided to executive officers. Mr. Sikri will also be entitled to reimbursement of all reasonable business expenses incurred or paid by him in the performance of his duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions set by the Company from time to time and to such reasonable substantiation and documentation as may be specified by the Company from time to time. If Mr. Sikri is terminated without cause or if Mr. Sikri terminates his employment for good reason, other than any such termination occurring during a change in control of the Company, the Company agrees to provide to Mr. Sikri as severance: (i) an amount equal to one times his base salary, (ii) an amount equal to one times his target bonus, (iii) reimbursement of premiums to continue health care benefits coverage under COBRA for the 12 months following the date of Mr. Sikri’s termination and (iv) accelerated vesting for time-based equity awards granted under the Company’s Amended and Restated Equity Incentive Plan that would have vested within 12 months of the termination date.
The summary of the Employment Agreement set forth above does not purport to be a complete statement of the terms of such document. The summary is qualified in its entirety by reference to the full text of the Employment Agreement, a form of which was filed as Exhibit 10.11 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 25, 2022.
Mr. Sikri does not have any family relationships with any of the Company’s other officers or directors.










Item 9.01
Financial Statements and Exhibits.

(a)Not applicable
(b)Not applicable
(c) Not applicable
(d) Exhibits.
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
By:/s/ William B. Bonello
Name:William B. Bonello
Title:Chief Financial Officer
Date:May 11, 2022


 EX-99.1 2 a99-1pressrelease592022.htm EX-99.1 Document

Exhibit 99.1

image.jpg

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

Ft. Myers, Florida – May 9, 2022 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris. Vishal will officially join NeoGenomics on May 23, 2022 and Dr. Morris will assist in the leadership transition over an appropriate handover period.
Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis leading all commercial operations. He has extensive precision medicine experience, having launched and commercialized tests for therapy selection and molecular residual disease in the U.S. and globally across different molecular platforms. Vishal brings years of proven success as a dynamic leader in large organizations. He holds degrees in Molecular Biology and Pharmaceutical Sciences from UW-Madison and an MBA from Loyola University.
"I am excited to join NeoGenomics and be part of a company that is a leader in the oncology space. It is an honor to join the team at this critical time and help launch innovative products like RaDaR that we expect will have a significant impact on cancer patients globally. There is still a lot of work to do to drive the adoption of precision medicine in oncology, especially in the community setting, but with this team and unwavering commitment, I am confident that we will continue to help lead this effort." said Vishal Sikri, President and Chief Commercial Officer of Inivata.
Dr. Clive Morris served as Inivata's top executive for 4 years, successfully guiding the company through the combination with NeoGenomics in June 2021. Prior to serving as Inivata's top executive, Dr. Morris served as Chief Medical Officer of Inivata, having joined the company in 2016. During his tenure, he oversaw a number of company successes including; multiple rounds of fundraising, the strategic partnership with and eventual sale to NeoGenomics, the clinical development and reimbursement process for InVisionFirst®-Lung, and pivot of the company toward RaDaR™, a leading assay for minimal residual and recurrence testing.
"We are pleased to announce the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and believe he has the skills needed to lead Inivata to further success. He has extensive experience in the precision oncology space and we will leverage his commercial expertise as we continue to move RaDaR forward with BioPharma and prepare for a launch into the clinical market." said Lynn Tetrault, Executive Chair of NeoGenomics.



Tetrault continued "We thank Clive for all his contributions as he moves on to his next adventure. Inivata reached a number of important milestones under his leadership and he guided the company through a successful acquisition process by NeoGenomics."
Separately, on Friday May 6th we issued an 8-K that the President of Pharma Services Division, Dr. Gina Wallar, is resigning from her position effective May 27, 2022 to pursue other professional opportunities. In connection with Dr. Wallar's departure, Ms. Jennifer Rose will assume interim responsibilities for the Pharma Services Division. Ms. Rose joined the Company in December 2015 and currently serves as our Vice President of Pharma Sales and Project Management Operations.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. We routinely post information that may be important to our investors on our website at www.neogenomics.com.
About Inivata
Inivata is the liquid biopsy focused subsidiary of the NeoGenomics, Inc. (NASDAQ: NEO) Group. Inivata's InVision® liquid biopsy platform unlocks essential genomic information from a simple blood draw which may be used by clinicians to guide personalized cancer treatment, to monitor response to treatment and to detect relapse. The commercially available InVisionFirst®-Lung test offers highly sensitive testing and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata's personalized RaDaR® assay allows the highly sensitive detection of residual disease and recurrence in certain cancers and has been granted Breakthrough Device Designation by the US FDA. Inivata is partnering with pharmaceutical, biotechnology companies and commercial entities in early through late-stage cancer development programs across a range of cancer types. The InVisionFirst®-Lung test and RaDaR are laboratory developed tests (LDTs) performed by Inivata's CLIA certified, CAP accredited laboratory in Research Triangle Park, North Carolina,


USA. Inivata also has R&D laboratories in Cambridge, UK. Inivata's technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge.
About RaDaR®
RaDaR is Inivata's assay for the detection of minimal residual disease (MRD) and recurrence. Built on Inivata's proven InVision® liquid biopsy platform technology, RaDaR is a highly sensitive personalized assay that tracks a set of up to 48 tumor-specific variants in a cancer patient's blood plasma. It is intended to detect residual disease following curative intent or definitive treatment, and to allow timely detection of relapse. RaDaR, a laboratory developed test (LDT), has been granted Breakthrough Device Designation by the US FDA.
Forward Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," expect," plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project, "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 25, 2022 as well as other information previously filed with the SEC.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

For further information, please contact:
NeoGenomics, Inc.
Doug Brown
Chief Strategy and Corporate Development Officer
T: 239.768.0600 x2539
M: 704.236.2064


doug.brown@neogenomics.com

Charlie Eidson
Director, Investor Relations and Corporate Development
T: 239.768.0600 x2726
M: 952.221.8816
charlie.eidson@neogenomics.com

Karen Chandler-Smith
SVP Marketing and Communications
Inivata
+44 (0)7900 430235
karen.chandler-smith@inivata.com

Inivata Media Contacts:
Consilium Strategic Communications
Chris Gardner/Angela Gray/Genevieve Wilson
Alix Floyd (US)
inivata@consilium-comms.com +44 (0)20 3709 5700

 EX-101.SCH 3 neo-20220505.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 neo-20220505_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Written Communications Written Communications City Area Code City Area Code Amendment Flag Amendment Flag Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 5 neo-20220505_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image.jpg begin 644 image.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 05, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 05, 2022
Entity Registrant Name NEOGENOMICS, INC.
Entity Central Index Key 0001077183
Amendment Flag false
Entity Incorporation, State or Country Code NV
Entity File Number 001-35756
Entity Tax Identification Number 74-2897368
Entity Address, Address Line One 9490 NeoGenomics Way,
Entity Address, City or Town Fort Myers,
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33912
City Area Code (239)
Local Phone Number 768-0600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock ($0.001 par value)
Trading Symbol NEO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 neo-20220505_htm.xml IDEA: XBRL DOCUMENT 0001077183 2022-05-05 2022-05-05 0001077183 false 8-K 2022-05-05 NEOGENOMICS, INC. NV 001-35756 74-2897368 9490 NeoGenomics Way, Fort Myers, FL 33912 (239) 768-0600 false false false false Common stock ($0.001 par value) NEO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://neogenomics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports neo-20220505.htm a99-1pressrelease592022.htm neo-20220505.xsd neo-20220505_lab.xml neo-20220505_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "neo-20220505.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "neo-20220505.htm" ] }, "labelLink": { "local": [ "neo-20220505_lab.xml" ] }, "presentationLink": { "local": [ "neo-20220505_pre.xml" ] }, "schema": { "local": [ "neo-20220505.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "neo", "nsuri": "http://neogenomics.com/20220505", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "neo-20220505.htm", "contextRef": "i60be9f81352e46b0974a5e9585db7d87_D20220505-20220505", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://neogenomics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "neo-20220505.htm", "contextRef": "i60be9f81352e46b0974a5e9585db7d87_D20220505-20220505", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001077183-22-000083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001077183-22-000083-xbrl.zip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end